As an HIV treatment drug, the side effects of Fostemsavir mainly involve liver dysfunction, gastrointestinal reactions, and immune system regulation. Through rational medication management and symptomatic treatment, adverse reactions can be effectively controlled.

Common side effects and treatment

(1) About 15% of patients with abnormal liver function experience elevated transaminase levels. It is recommended to monitor ALT/AST levels before treatment and during the 4th and 12th weeks of treatment. Mild abnormalities (<5 times ULN) can continue medication and strengthen monitoring, while severe abnormalities require discontinuation of medication and liver protection treatment.

(2) Gastrointestinal reactions

Nausea (12%) and diarrhea (9%) are more common in the early stages of medication. It is recommended to take it with meals to reduce irritation. For persistent symptoms, antiemetic drugs such as ondansetron can be considered. Dehydrated patients need to supplement electrolytes.

Dealing with serious side effects

(3) Immune reconstitution inflammatory syndrome usually occurs after 2-8 weeks of treatment, characterized by fever and lymph node enlargement. It needs to be differentiated from infection recurrence, and in severe cases, prednisone 0.5mg/kg/d can be used for a short period of time to control the inflammatory response.

(4) Allergic reactions

The incidence of rash is about 5%, and if there is widespread erythema or mucosal damage, the medication should be stopped immediately. Severe allergies require adrenaline rescue and the medication should be permanently discontinued.

Special management measures

(5) Cardiovascular monitoring may cause QT interval prolongation, and baseline electrocardiogram examination is required before medication. Avoid co administration with fluoroquinolones, tricyclic antidepressants, etc. Elderly patients should pay special attention to monitoring.

(6) Metabolic management

Common blood lipid abnormalities (10-15% increase in total cholesterol), it is recommended to test the blood lipid profile every 3 months during treatment. Patients with combined cardiovascular risk need to initiate statin therapy simultaneously.

Storage temperature requirements

(1) Unopened state should be stored at room temperature of 20 ° C to 25 ° C (68 ° F to 77 ° F), with a short-term temperature fluctuation range of 15 ° C to 30 ° C (59 ° F to 86 ° F) allowed. The original packaging should be kept intact and protected from light and moisture.